Daniel Long's most recent trade in Septerna Inc. was a trade of 3,333 Common Stock done at an average price of $2.8 . Disclosure was reported to the exchange on July 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Septerna Inc | Daniel Long | SVP, Drug Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.76 per share. | 01 Jul 2026 | 3,333 | 99,745 | - | 2.8 | 9,199 | Common Stock |
| Septerna Inc | Daniel Long | SVP, Drug Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2026 | 3,333 | 7,043 | - | - | Stock Option (Right to Buy) | |
| Septerna Inc | Daniel Long | SVP, Drug Discovery | Sale of securities on an exchange or to another person at price $ 34.10 per share. | 01 Jul 2026 | 2,100 | 97,645 | - | 34.1 | 71,602 | Common Stock |
| Septerna Inc | Daniel Long | SVP, Drug Discovery | Sale of securities on an exchange or to another person at price $ 34.81 per share. | 01 Jul 2026 | 1,233 | 96,412 | - | 34.8 | 42,926 | Common Stock |
| Septerna Inc | Daniel Long | SVP, Drug Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.76 per share. | 22 Jun 2026 | 10,529 | 106,941 | - | 2.8 | 29,060 | Common Stock |
| Septerna Inc | Daniel Long | SVP, Drug Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2026 | 10,529 | 10,376 | - | - | Stock Option (Right to Buy) | |
| Septerna Inc | Daniel Long | SVP, Drug Discovery | Sale of securities on an exchange or to another person at price $ 35.10 per share. | 22 Jun 2026 | 8,000 | 103,412 | - | 35.1 | 280,801 | Common Stock |
| Septerna Inc | Daniel Long | SVP, Drug Discovery | Sale of securities on an exchange or to another person at price $ 35.97 per share. | 22 Jun 2026 | 7,000 | 96,412 | - | 36.0 | 251,781 | Common Stock |
| Septerna Inc | Daniel Long | SVP, Drug Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2026 | 4,471 | 25,529 | - | - | Stock Option (Right to Buy) | |
| Septerna Inc | Daniel Long | SVP, Drug Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.70 per share. | 22 Jun 2026 | 4,471 | 111,412 | - | 11.7 | 52,311 | Common Stock |
| Septerna Inc | Daniel Long | SVP, Drug Discovery | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2026 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Septerna Inc | Daniel Long | SVP, Drug Discovery | Sale of securities on an exchange or to another person at price $ 18.06 per share. | 10 Nov 2025 | 3,501 | 92,911 | - | 18.1 | 63,223 | Common Stock |
| Septerna Inc | Daniel Long | SVP, Drug Discovery | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) |